Combinatorial epigenetic mechanisms of sulforaphane, genistein and sodium butyrate in breast cancer inhibition

Exp Cell Res. 2022 Jul 1;416(1):113160. doi: 10.1016/j.yexcr.2022.113160. Epub 2022 Apr 18.

Abstract

Dietary phytochemicals are currently being studied with great interest due to their ability to regulate the epigenome resulting in prevention of cancer. Some natural botanicals have been reported to have enhanced and synergistic impact on cancer suppression when administered at optimum concentrations and in-conjunction. Sulforaphane (SFN) is an isothiocyanate found in cruciferous vegetables and sodium butyrate (NaB) is a short-chain fatty acid produced by gut microbiota. They have been intensively explored due to numerous anti-cancerous properties and ability to modulate epigenetic machinery by inhibition of histone deacetylase (HDAC). Genistein (GE), present in soy, is a known DNA methyltransferase (DNMT) inhibitor. While combined chemoprotective epigenetic effects induced by SFN and GE have been investigated, the key impact of combinatorial SFN-NaB, GE-NaB, and SFN-GE-NaB bioactive components in regulation of various mechanisms are poorly defined. In the present study, we found that combinations of dietary compounds had synergistic effects in decreasing cellular viability at lower dosages than their single dosages in breast cancer cell lines. The respective combinations limited growth and increased apoptosis and necrosis in cancerous cells among which the tri-combination displayed the most significant impact. Additionally, the respective combinations of compounds arrested MDA-MB-231 and MCF-7 breast cancer cells at G2/M phase. Our further mechanistic evaluation revealed that respective di-combinations and tri-combination had higher impact in down-regulation of DNMTs (DNMT3A and DNMT3B), HDACs (HDAC1, HDAC6 and HDAC11), histone methyltransferases (EZH2 and SUV39H1) and histone acetyltransferases (GCN5, PCAF, P300 and CBP) levels as compared to singly administered compounds. We also found that these combinations exhibited global epigenetic changes by inhibition of DNMT and HDAC activity, histone H3 at lysine 27 methylation (H3K27me) and histone H3 at lysine 9 methylation (H3K9me) levels, and by induction of histone acetyltransferases activity. Collectively, our investigation indicates that combined SFN, GE and NaB is highly effective in inhibiting breast cancer genesis by, at least in part, regulating epigenetic modifications, which may have implications in breast cancer therapy.

Keywords: Breast cancer; Combinatorial; Epigenetics; Genistein; Sodium butyrate; Sulforaphane; Therapy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Apoptosis
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Butyric Acid / pharmacology
  • Cell Line, Tumor
  • Epigenesis, Genetic
  • Female
  • Genistein / pharmacology
  • Histone Acetyltransferases / metabolism
  • Histone Deacetylase Inhibitors / pharmacology
  • Histones / metabolism
  • Humans
  • Isothiocyanates / pharmacology
  • Lysine / metabolism
  • Sulfoxides

Substances

  • Histone Deacetylase Inhibitors
  • Histones
  • Isothiocyanates
  • Sulfoxides
  • Butyric Acid
  • Genistein
  • Histone Acetyltransferases
  • sulforaphane
  • Lysine